CVS Health Corporation (CVS)
NYSE: CVS · Real-Time Price · USD
63.48
-1.61 (-2.47%)
At close: Feb 21, 2025, 4:00 PM
63.36
-0.12 (-0.20%)
After-hours: Feb 21, 2025, 7:50 PM EST
CVS Health Stock Forecast
Stock Price Forecast
The 16 analysts with 12-month price forecasts for CVS Health stock have an average target of 69.75, with a low estimate of 58 and a high estimate of 81. The average target predicts an increase of 9.88% from the current stock price of 63.48.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for CVS Health stock from 16 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 6 | 7 | 6 | 5 |
| Buy | 5 | 7 | 7 | 7 | 7 | 8 |
| Hold | 7 | 5 | 4 | 3 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 18 | 18 | 17 | 17 | 16 | 16 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| JP Morgan | JP Morgan | Buy Maintains $80 → $81 | Buy | Maintains | $80 → $81 | +27.60% | Feb 18, 2025 |
| Wells Fargo | Wells Fargo | Buy Maintains $68 → $73 | Buy | Maintains | $68 → $73 | +15.00% | Feb 13, 2025 |
| Truist Securities | Truist Securities | Strong Buy Maintains $60 → $76 | Strong Buy | Maintains | $60 → $76 | +19.72% | Feb 13, 2025 |
| Barclays | Barclays | Buy Maintains $71 → $73 | Buy | Maintains | $71 → $73 | +15.00% | Feb 13, 2025 |
| Leerink Partners | Leerink Partners | Hold → Buy Upgrades $55 → $75 | Hold → Buy | Upgrades | $55 → $75 | +18.15% | Feb 13, 2025 |
Financial Forecast
Revenue This Year
392.22B
from 370.66B
Increased by 5.82%
Revenue Next Year
412.41B
from 392.22B
Increased by 5.15%
EPS This Year
5.97
from 3.66
Increased by 63.08%
EPS Next Year
6.95
from 5.97
Increased by 16.50%
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 416.9B | 446.1B | 482.4B | ||
| Avg | 392.2B | 412.4B | 434.2B | ||
| Low | 363.1B | 371.9B | 387.3B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 12.5% | 13.7% | 17.0% | ||
| Avg | 5.8% | 5.1% | 5.3% | ||
| Low | -2.0% | -5.2% | -6.1% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 6.83 | 7.97 | 9.45 | ||
| Avg | 5.97 | 6.95 | 7.92 | ||
| Low | 5.45 | 6.14 | 6.50 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 86.5% | 33.5% | 35.9% | ||
| Avg | 63.1% | 16.5% | 13.9% | ||
| Low | 48.9% | 2.8% | -6.5% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.